17β-HSD

17β-Hydroxysteroid dehydrogenase (17β-HSD) inhibitors in this category mostly target one aldo-keto reductase. Aldo-keto reductase family 1 member C3 (AKR1C3), also called type 5 17β-HSD, reduces androstenedione to testosterone in peripheral tissues. Its close relatives AKR1C1 and AKR1C2 act mainly on other steroids, inactivating progesterone and 5α-dihydrotestosterone. These isoforms share high sequence identity, so selectivity between them is a central question in inhibitor research. AKR1C3-IN-1 and AKR1C2/3-IN-1 address AKR1C3, while AKR1C1-IN-1 is directed at AKR1C1. Stylopine, a protoberberine alkaloid, is also listed as an AKR1C3 inhibitor. AKR1B10-IN-1 targets AKR1B10, a reductase of a neighboring subfamily that is studied in retinoid and lipid metabolism.

Items 76-100 of 149

  • HSD17B13-IN-102
    Cat. No.
    A69038

    HSD17B13-IN-102

    HSD17B13-IN-102 is a potent inhibitor of the enzyme hydroxysteroid dehydrogenase 17 beta 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM with estradiol. This compound is instrumental in research focused on steroid metabolism and associated diseases, particularly in the context of liver function and metabolic disorders. Its selective inhibition provides a valuable tool for investigating the biological roles of HSD17B13 in various physiological and pathological conditions.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-16
    Cat. No.
    A69039

    HSD17B13-IN-16

    HSD17B13-IN-16 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound has significant relevance in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-16 serves as a valuable tool for researchers investigating metabolic disorders and potential therapeutic interventions in liver diseases.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-35
    Cat. No.
    A69040

    HSD17B13-IN-35

    HSD17B13-IN-35 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM when estradiol is used as a substrate. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), by targeting metabolic pathways involved in lipid metabolism. Its effective inhibition of HSD17B13 makes it a valuable reagent for research into therapeutic strategies for liver-related disorders.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-63
    Cat. No.
    A69041

    HSD17B13-IN-63

    HSD17B13-IN-63 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research applications related to liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its efficacy in modulating HSD17B13 activity provides insights into the underlying mechanisms of these diseases.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-57
    Cat. No.
    A69042

    HSD17B13-IN-57

    HSD17B13-IN-57 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is relevant for investigations into liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-57 serves as a valuable tool for studying the biochemical pathways involved in these diseases.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-28
    Cat. No.
    A69043

    HSD17B13-IN-28

    HSD17B13-IN-28 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol as substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its ability to modulate HSD17B13 activity makes it a valuable tool for exploring the metabolic mechanisms underpinning liver disorders and evaluating potential therapeutic strategies.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-100
    Cat. No.
    A69044

    HSD17B13-IN-100

    HSD17B13-IN-100 is a potent inhibitor of HSD17B13, exhibiting an IC50 value of less than 0.1 μM in the presence of estradiol. This compound is essential for researchers investigating the role of HSD17B13 in steroid metabolism and related pathways. Its selective inhibition can facilitate studies on various conditions associated with altered steroidogenesis, including liver diseases and metabolic disorders.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-80
    Cat. No.
    A69045

    HSD17B13-IN-80

    HSD17B13-IN-80 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound plays a crucial role in research focusing on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibitory activity makes it a valuable tool for investigating the pathophysiological mechanisms underlying these diseases.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-44
    Cat. No.
    A69046

    HSD17B13-IN-44

    HSD17B13-IN-44 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for investigating its role in liver diseases and metabolic disorders, providing insights into the biochemical pathways associated with these conditions. Researchers can utilize HSD17B13-IN-44 to explore therapeutic targets and validate the significance of HSD17B13 in various biological processes.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-45
    Cat. No.
    A69047

    HSD17B13-IN-45

    HSD17B13-IN-45 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is instrumental in exploring pathways associated with liver diseases and metabolic disorders. Researchers can utilize HSD17B13-IN-45 to investigate the role of HSD17B13 in various biological contexts and its potential as a therapeutic target.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-81
    Cat. No.
    A69048

    HSD17B13-IN-81

    HSD17B13-IN-81 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is utilized in research focused on liver diseases, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, it serves as a valuable tool in studies related to drug-induced liver injury (DILI).

    Out of stock

    All 3 sizes
  • HSD17B13-IN-40
    Cat. No.
    A69049

    HSD17B13-IN-40

    HSD17B13-IN-40 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 of less than 0.1 μM against estradiol substrates. This compound is significant for research related to nonalcoholic fatty liver diseases (NAFLD), particularly nonalcoholic steatohepatitis (NASH), as it may provide insights into the modulation of lipid metabolism and inflammatory pathways. The compound's inhibitory action on HSD17B13 highlights its potential utility in exploring therapeutic strategies for metabolic disorders.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-58
    Cat. No.
    A69050

    HSD17B13-IN-58

    HSD17B13-IN-58 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in the research of nonalcoholic fatty liver diseases (NAFLD), contributing to the understanding of lipid metabolism and hormonal regulation in hepatic disorders. Its selective inhibition offers valuable insights into therapeutic strategies targeting HSD17B13 in liver-related diseases.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-33
    Cat. No.
    A69051

    HSD17B13-IN-33

    HSD17B13-IN-33 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound plays a crucial role in research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective activity makes it a valuable tool for investigating the therapeutic potential in these diseases.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-30
    Cat. No.
    A69052

    HSD17B13-IN-30

    HSD17B13-IN-30 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol substrates. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), due to its role in modulating steroid metabolism and fatty liver progression. HSD17B13-IN-30 facilitates research into therapeutic approaches for liver-related metabolic disorders.

    Out of stock

    All 3 sizes
  • 17β-HSD1-IN-2
    Cat. No.
    A69053

    17β-HSD1-IN-2

    17β-HSD1-IN-2 is a non-estrogenic, steroidal covalent irreversible inhibitor of 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting a Ki of 368 nM. This compound demonstrates potential for studying estrogen-dependent disorders, facilitating research into therapeutic strategies for conditions influenced by estrogen metabolism. Its selective inhibition of 17β-HSD1 offers valuable insights into the enzyme's role in various biological processes and disease states.

    1 mg
    $620.00
    5 mg
    $1,305.00
    All 5 sizes
  • HSD17B13-IN-14
    Cat. No.
    A69054

    HSD17B13-IN-14

    HSD17B13-IN-14 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is valuable for research into hepatic conditions, metabolic diseases, and cardiovascular disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition of HSD17B13 makes it an important tool for studying the underlying mechanisms of these diseases.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-53
    Cat. No.
    A69056

    HSD17B13-IN-53

    HSD17B13-IN-53 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver-related pathologies, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies on drug-induced liver injury (DILI).

    Out of stock

    All 3 sizes
  • HSD17B13-IN-47
    Cat. No.
    A69057

    HSD17B13-IN-47

    HSD17B13-IN-47 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for studying the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into therapeutic interventions targeting these conditions.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-83
    Cat. No.
    A69058

    HSD17B13-IN-83

    HSD17B13-IN-83 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is relevant for investigations into liver and metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specificity and efficacy make it a valuable tool for advancing research in the fields of hepatology and cardiovascular health.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-34
    Cat. No.
    A69060

    HSD17B13-IN-34

    HSD17B13-IN-34 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily deployed in research related to nonalcoholic fatty liver disease (NAFLD), facilitating the investigation of HSD17B13's role in lipid metabolism and liver function. Its selective inhibition offers valuable insights into therapeutic strategies targeting dysregulated steroid metabolism in hepatic disorders.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-56
    Cat. No.
    A69061

    HSD17B13-IN-56

    HSD17B13-IN-56 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is crucial for investigating the role of HSD17B13 in various hepatic and metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition makes it a valuable tool for advancing research in liver pathology and associated cardiovascular conditions.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-51
    Cat. No.
    A69062

    HSD17B13-IN-51

    HSD17B13-IN-51 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as drug-induced liver injury (DILI). Its specific targeting of HSD17B13 positions it as a critical tool for investigating metabolic and cardiovascular disease pathways.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-105
    Cat. No.
    A69063

    HSD17B13-IN-105

    HSD17B13-IN-105 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase 13 (17BHSD13), exhibiting an IC50 value of 0.036 μM and notable selectivity against 17BHSD4 with an IC50 of 31.5 μM. This compound is valuable for research applications targeting liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its specificity and potent inhibition profile make it a significant tool for studying the biochemical pathways involved in these conditions.

    Out of stock

    All 3 sizes
  • HSD17B13-IN-48
    Cat. No.
    A69064

    HSD17B13-IN-48

    HSD17B13-IN-48 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibitory action on HSD17B13 makes it a crucial tool for research into the pathophysiology and therapeutic targeting of these conditions.

    Out of stock

    All 3 sizes

Items 76-100 of 149

Added to your cart

View Cart Checkout

    Loading...